Acute GVHD Clinical Trial
Official title:
Ruxolitinib and Methylprednisolone as First Line Therapy for Acute Graft Versus Host Disease Following Allogeneic Stem Cell Transplantation
The purpose of this study is to evaluate the efficacy of ruxolitinib in combination with methylprednisolone as first line therapy in patients with Grades II to IV acute graft-versus-host disease (GVHD).
Treatment:
Once patients are diagnosed with grade II~IV acute GVHD, the combination therapy should be
initiated as soon as possible.
1. Methylprednisolone: 2mg/kg/d, iv or iv gtt, in two or three divided doses. Taper steroid
every one or two weeks according to patient's response.
2. Ruxolitinib 5~10mg bid po for at least 28 days. If patient's ANC<0.5×10e9/L or PLT<
20×10e9/L, cease ruxolitinib until recovery of ANC higher than 0.5×10e9/L or PLT higher
than 20×10e9/L.
Indication for stopping Ruxolitinib treatment:
1. No response after ruxolitinib treatment for 28 days.
2. Develop life-threatening complication.
3. ANC<0.5×10e9/L or PLT< 20×10e9/L.
Indication for second line acute GVHD treatment:
1. deterioration of acute GVHD in 3 days
2. no response after 7 days
3. no complete remission after 2 weeks.
Suggestions of second line therapy:
Basiliximab 20mg, d1, d4, d8.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02806947 -
A Study to Evaluate Steroid-free Treatment for Standard-Risk aGVHD (BMT CTN 1501)
|
Phase 2 | |
Completed |
NCT02631993 -
Photochemotherapy and Graft-versus-leukemia in Acute-leukemia
|
N/A | |
Terminated |
NCT01530256 -
Exploratory Safety Study of ALD518 in Subjects With Steroid-refractory Acute Graft Versus Host Disease (GVHD)
|
Phase 1/Phase 2 | |
Recruiting |
NCT04373057 -
Prebiotic Galacto-oligosaccharide and Acute GVHD
|
Phase 1/Phase 2 | |
Completed |
NCT04645667 -
Tacrolimus in Allogeneic Hematopoietic Stem Cell Transplant (HCT)
|
||
Completed |
NCT00350181 -
Sirolimus & Mycophenolate Mofetil as GVHD Prophylaxis in Myeloablative, Matched Related Donor HCT
|
Phase 2 | |
Recruiting |
NCT02611180 -
Dendritic Cells in Patients With Acute or Chronic Skin Graft Versus Host Disease
|
||
Recruiting |
NCT05263999 -
A Study of Itolizumab in Combination With Corticosteroids for the First-Line Treatment of Acute Graft Versus Host Disease (EQUATOR)
|
Phase 3 |